- Home
- PRLB vs URGN Comparison
PRLB vs URGN Comparison
Compare PRLB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLB
- URGN
- Stock Information
- Founded
- PRLB 1999
- URGN 2004
- Country
- PRLB United States
- URGN United States
- Employees
- PRLB N/A
- URGN N/A
- Industry
- PRLB Metal Fabrications
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- PRLB Industrials
- URGN Health Care
- Exchange
- PRLB Nasdaq
- URGN Nasdaq
- Market Cap
- PRLB 928.0M
- URGN 904.0M
- IPO Year
- PRLB 2012
- URGN 2017
- Fundamental
- Price
- PRLB $49.97
- URGN $18.88
- Analyst Decision
- PRLB Hold
- URGN Strong Buy
- Analyst Count
- PRLB 3
- URGN 8
- Target Price
- PRLB $43.50
- URGN $28.50
- AVG Volume (30 Days)
- PRLB 167.8K
- URGN 1.0M
- Earning Date
- PRLB 10-31-2025
- URGN 11-05-2025
- Dividend Yield
- PRLB N/A
- URGN N/A
- EPS Growth
- PRLB N/A
- URGN N/A
- EPS
- PRLB 0.61
- URGN N/A
- Revenue
- PRLB $508,637,000.00
- URGN $94,238,000.00
- Revenue This Year
- PRLB $6.30
- URGN $35.60
- Revenue Next Year
- PRLB $4.89
- URGN $129.54
- P/E Ratio
- PRLB $82.10
- URGN N/A
- Revenue Growth
- PRLB N/A
- URGN 10.85
- 52 Week Low
- PRLB $26.35
- URGN $3.42
- 52 Week High
- PRLB $51.09
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- PRLB 63.86
- URGN 51.50
- Support Level
- PRLB $48.59
- URGN $18.17
- Resistance Level
- PRLB $50.93
- URGN $20.20
- Average True Range (ATR)
- PRLB 1.11
- URGN 0.90
- MACD
- PRLB -0.25
- URGN -0.24
- Stochastic Oscillator
- PRLB 72.15
- URGN 34.98
About PRLB Proto Labs Inc. Common stock
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.